Alcon Canada Earns Global Recognition as a Top Employer
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a recognized authority on identifying excellence in people practices and workplace culture. Being certified as a Top Employer showcases Alcon Canada's commitment to building a better world of work through exceptional HR policies and forward-thinking people practices. This recog.
Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System
Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years
Alcon Stock Rises Following the FDA Approval of TRYPTYR
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
US FDA approves Alcon's new dry-eye drug
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more
The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses. The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses.
Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript
Alcon Inc. (NYSE:ALC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Jack Reynolds-Clark - RBC Capital Markets Graham Doyle - UBS Ryan Zimmerman - BTIG David Saxon - Needham & Company Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Anthony Petrone - Mizuho Group Tom Stephan - Stifel Brett Fishbin - KeyBanc Capital Markets Young Li - Jefferies Jeff Johnson - Baird David Adlington - JPMorgan Operator Greetings, and welcome to the Alcon First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode.
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
ALC ends the first quarter of 2025 on a disappointing note.
Alcon (ALC) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Alcon (ALC) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
ALC Stock May Rise With the Introduction of PanOptix Pro in US
Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected in May.
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
GENEVA--(BUSINESS WIRE)--Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter.
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
